To summarize, this study was the first to unveil the role and molecular mechanism of LINC01232, expounding that SP1-induced LINC01232 exerted oncogenic activities in PAAD via recruiting EIF4A3 to upregulate TM9SF2 expression (Fig. 8). Here, TM9SF2 is linked to pancreatic adenocarcinoma.